Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects
Abstract It is reported that pulmonary fibrosis has become one of the major long-term complications of COVID-19, even in asymptomatic individuals. Currently, despite the best efforts of the global medical community, there are no treatments for COVID-induced pulmonary fibrosis. Recently, inhalable na...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-023-01971-7 |
| _version_ | 1797784456234270720 |
|---|---|
| author | Qianyu Wan Xinrui Zhang Dongfang Zhou Rui Xie Yue Cai Kehao Zhang Xuanrong Sun |
| author_facet | Qianyu Wan Xinrui Zhang Dongfang Zhou Rui Xie Yue Cai Kehao Zhang Xuanrong Sun |
| author_sort | Qianyu Wan |
| collection | DOAJ |
| description | Abstract It is reported that pulmonary fibrosis has become one of the major long-term complications of COVID-19, even in asymptomatic individuals. Currently, despite the best efforts of the global medical community, there are no treatments for COVID-induced pulmonary fibrosis. Recently, inhalable nanocarriers have received more attention due to their ability to improve the solubility of insoluble drugs, penetrate biological barriers of the lungs and target fibrotic tissues in the lungs. The inhalation route has many advantages as a non-invasive method of administration and the local delivery of anti-fibrosis agents to fibrotic tissues like direct to the lesion from the respiratory system, high delivery efficiency, low systemic toxicity, low therapeutic dose and more stable dosage forms. In addition, the lung has low biometabolic enzyme activity and no hepatic first-pass effect, so the drug is rapidly absorbed after pulmonary administration, which can significantly improve the bioavailability of the drug. This paper summary the pathogenesis and current treatment of pulmonary fibrosis and reviews various inhalable systems for drug delivery in the treatment of pulmonary fibrosis, including lipid-based nanocarriers, nanovesicles, polymeric nanocarriers, protein nanocarriers, nanosuspensions, nanoparticles, gold nanoparticles and hydrogel, which provides a theoretical basis for finding new strategies for the treatment of pulmonary fibrosis and clinical rational drug use. |
| first_indexed | 2024-03-13T00:40:08Z |
| format | Article |
| id | doaj.art-df1d5254a086406092f6678bb8876385 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-03-13T00:40:08Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-df1d5254a086406092f6678bb88763852023-07-09T11:23:36ZengBMCJournal of Nanobiotechnology1477-31552023-07-0121112210.1186/s12951-023-01971-7Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospectsQianyu Wan0Xinrui Zhang1Dongfang Zhou2Rui Xie3Yue Cai4Kehao Zhang5Xuanrong Sun6Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of TechnologyCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of TechnologyZhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., LtdCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of TechnologyCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of TechnologyCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of TechnologyCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of TechnologyAbstract It is reported that pulmonary fibrosis has become one of the major long-term complications of COVID-19, even in asymptomatic individuals. Currently, despite the best efforts of the global medical community, there are no treatments for COVID-induced pulmonary fibrosis. Recently, inhalable nanocarriers have received more attention due to their ability to improve the solubility of insoluble drugs, penetrate biological barriers of the lungs and target fibrotic tissues in the lungs. The inhalation route has many advantages as a non-invasive method of administration and the local delivery of anti-fibrosis agents to fibrotic tissues like direct to the lesion from the respiratory system, high delivery efficiency, low systemic toxicity, low therapeutic dose and more stable dosage forms. In addition, the lung has low biometabolic enzyme activity and no hepatic first-pass effect, so the drug is rapidly absorbed after pulmonary administration, which can significantly improve the bioavailability of the drug. This paper summary the pathogenesis and current treatment of pulmonary fibrosis and reviews various inhalable systems for drug delivery in the treatment of pulmonary fibrosis, including lipid-based nanocarriers, nanovesicles, polymeric nanocarriers, protein nanocarriers, nanosuspensions, nanoparticles, gold nanoparticles and hydrogel, which provides a theoretical basis for finding new strategies for the treatment of pulmonary fibrosis and clinical rational drug use.https://doi.org/10.1186/s12951-023-01971-7InhalationNano-based drug delivery systemPulmonary fibrosisCOVID-19 |
| spellingShingle | Qianyu Wan Xinrui Zhang Dongfang Zhou Rui Xie Yue Cai Kehao Zhang Xuanrong Sun Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects Journal of Nanobiotechnology Inhalation Nano-based drug delivery system Pulmonary fibrosis COVID-19 |
| title | Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects |
| title_full | Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects |
| title_fullStr | Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects |
| title_full_unstemmed | Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects |
| title_short | Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects |
| title_sort | inhaled nano based therapeutics for pulmonary fibrosis recent advances and future prospects |
| topic | Inhalation Nano-based drug delivery system Pulmonary fibrosis COVID-19 |
| url | https://doi.org/10.1186/s12951-023-01971-7 |
| work_keys_str_mv | AT qianyuwan inhalednanobasedtherapeuticsforpulmonaryfibrosisrecentadvancesandfutureprospects AT xinruizhang inhalednanobasedtherapeuticsforpulmonaryfibrosisrecentadvancesandfutureprospects AT dongfangzhou inhalednanobasedtherapeuticsforpulmonaryfibrosisrecentadvancesandfutureprospects AT ruixie inhalednanobasedtherapeuticsforpulmonaryfibrosisrecentadvancesandfutureprospects AT yuecai inhalednanobasedtherapeuticsforpulmonaryfibrosisrecentadvancesandfutureprospects AT kehaozhang inhalednanobasedtherapeuticsforpulmonaryfibrosisrecentadvancesandfutureprospects AT xuanrongsun inhalednanobasedtherapeuticsforpulmonaryfibrosisrecentadvancesandfutureprospects |